Elaine Heron
Director/Board Member at BIOMARIN PHARMACEUTICAL INC.
Net worth: 8 M $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Susan Dillon | M | - |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | 6 years |
Robert Emanuele | M | 69 |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
Paul Russo | M | 81 | 25 years | |
Michael Finney | M | 65 | 17 years | |
Elizabeth Anderson | F | 66 |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | 6 years |
Todd Davis | M | 63 |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | 7 years |
Jean-Jacques Bienaimé | M | 70 | 19 years | |
Mark Laurenzi | M | - |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | - |
Wesley H. Kaupinen | M | - |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | 9 years |
Karyn O’Neil | M | - |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | 6 years |
Santosh Vetticaden | M | 65 |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
Randy Meier | M | 65 | 18 years | |
Sean Tucker | M | - | 20 years | |
Jeff Ajer | M | 61 | 19 years | |
Richard Nathan Ellson | M | - |
Labcyte, Inc.
Labcyte, Inc. Medical/Nursing ServicesHealth Services Labcyte, Inc. operates as a biotechnology tools company that manufactures and markets echo liquid handling systems. It offers liquid handling, automation and consumables. The company was founded by Richard Nathan Ellson and Mark D. Fischer-Colbrie and A. Mark Bramwell in October 2003 and is headquartered in Sunnyvale, CA. | 21 years |
Alexander Hardy | M | 56 | 1 years | |
William Pedranti | M | - |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | 1 years |
David Wheadon | M | 66 | 3 years | |
Athena Countouriotis | M | 52 | 1 years | |
David Pyott | M | 70 | 8 years | |
Dennis Joseph Slamon | M | 75 | 10 years | |
Kelly Gardner | M | - |
Zephyrus Biosciences, Inc.
Zephyrus Biosciences, Inc. BiotechnologyHealth Technology Zephyrus Biosciences, Inc. provides tools for protein analysis at the single cell level. The firm's products include Z1 instrument, zWest Kits, and scWestern system which enables western blotting on individual cells. Its products are used to gain insights into the biology of cancer, stem cells, neurology, and human disease and development. The company was founded by Kelly Gardner, Amy E. Herr and Joshua Molho in 2013 and is headquartered in Berkeley, CA. | 11 years |
Joshua Molho | M | - |
Zephyrus Biosciences, Inc.
Zephyrus Biosciences, Inc. BiotechnologyHealth Technology Zephyrus Biosciences, Inc. provides tools for protein analysis at the single cell level. The firm's products include Z1 instrument, zWest Kits, and scWestern system which enables western blotting on individual cells. Its products are used to gain insights into the biology of cancer, stem cells, neurology, and human disease and development. The company was founded by Kelly Gardner, Amy E. Herr and Joshua Molho in 2013 and is headquartered in Berkeley, CA. | 11 years |
Barbara Bodem | F | 56 | 1 years | |
Scott Greenberg | M | - |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | 5 years |
Edward Berg | M | - | 6 years | |
Willard Dere | M | 70 | 8 years | |
Philip Lo Scalzo | M | - | 17 years | |
Stuart Bunting | M | - | 16 years | |
George Davis | M | 53 | 20 years | |
Robert Hombach | M | 58 | 7 years | |
Robert Yedid | M | 66 | 5 years | |
Simon P. Westbrook | M | 75 | 6 years | |
Bruce Peacock | M | 72 |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | - |
V. Lawlis | M | 72 | 17 years | |
May Kin Ho | M | 71 | 3 years | |
Chris Mirabelli | M | 69 |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | 4 years |
Mark Alles | M | 64 | 2 years | |
Mark Enyedy | M | 60 | 1 years | |
Brian Mueller | M | 50 | 22 years | |
Marni Kottle | F | - | - | |
Ganesh Vedantham | M | - | 3 years | |
Deborah Baron | F | 55 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
Daniel L. Chao | M | - |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
Michael Christopher | M | - |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | - |
Timothy J. Henkel | M | 65 |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | - |
Adam Dinerman | M | - |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | - |
C. Guyer | M | 62 | - | |
Erin Burkhart | F | 45 | 2 years | |
Amy Wireman | F | - | 11 years | |
Humaira Serajuddin | F | - | 2 years | |
Eric Carter | M | 72 |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | 2 years |
Phillip Eric Lee | M | 37 | 2 years | |
Thomas Meier | M | - |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | - |
Dave Jacoby | M | - | 8 years | |
Traci McCarty | F | - | - | |
Garnet Peck | M | 93 |
Purdue University
| 57 years |
John Doux | M | - |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | - |
Chris LeMasters | M | - |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 4 years |
Douglas Crawford | M | - |
Zephyrus Biosciences, Inc.
Zephyrus Biosciences, Inc. BiotechnologyHealth Technology Zephyrus Biosciences, Inc. provides tools for protein analysis at the single cell level. The firm's products include Z1 instrument, zWest Kits, and scWestern system which enables western blotting on individual cells. Its products are used to gain insights into the biology of cancer, stem cells, neurology, and human disease and development. The company was founded by Kelly Gardner, Amy E. Herr and Joshua Molho in 2013 and is headquartered in Berkeley, CA. | - |
Marten Steen | M | 49 |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | - |
Anand Mehra | M | 48 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
Thomas Meier | M | 62 |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | 2 years |
Jon Saxe | M | 88 | 3 years | |
George M. Jenkins | M | - |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | - |
William Mark Watson | M | 73 | 2 years | |
Cory Freedland | M | 48 |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | - |
Amy E. Herr | M | - |
Zephyrus Biosciences, Inc.
Zephyrus Biosciences, Inc. BiotechnologyHealth Technology Zephyrus Biosciences, Inc. provides tools for protein analysis at the single cell level. The firm's products include Z1 instrument, zWest Kits, and scWestern system which enables western blotting on individual cells. Its products are used to gain insights into the biology of cancer, stem cells, neurology, and human disease and development. The company was founded by Kelly Gardner, Amy E. Herr and Joshua Molho in 2013 and is headquartered in Berkeley, CA. | 11 years |
Raymond Stapleton | M | - | 2 years | |
James Cummings | M | - | 3 years | |
Kevin Eggan | M | - | 4 years | |
Mark Herr | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Andrei Floroiu | M | 51 | 4 years | |
Ciara Kennedy | M | 52 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
Michael Grey | M | 71 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 16 years |
Mark D. Fischer-Colbrie | M | 67 |
Labcyte, Inc.
Labcyte, Inc. Medical/Nursing ServicesHealth Services Labcyte, Inc. operates as a biotechnology tools company that manufactures and markets echo liquid handling systems. It offers liquid handling, automation and consumables. The company was founded by Richard Nathan Ellson and Mark D. Fischer-Colbrie and A. Mark Bramwell in October 2003 and is headquartered in Sunnyvale, CA. | 16 years |
Pierre LaPalme | M | 83 | 12 years | |
Adora Ndu | M | 43 | 5 years | |
Frederick Dale Fischer | M | 73 |
Purdue University
| 5 years |
Marwan Al-Mouasher | M | 67 |
Purdue University
| 8 years |
Mitchell Mutz | M | 61 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 10 years |
James A. Tompkins | M | - |
Purdue University
| 7 years |
Stephen Brand | M | 74 |
Purdue University
| 4 years |
Carl Adams | M | - |
Purdue University
| 4 years |
Sandra Shpilberg | F | 48 | 9 years | |
Paul W. Hemmer | M | - |
Purdue University
| 5 years |
Harold C. Smith | M | - |
Purdue University
| 7 years |
W. Dwight Armstrong | M | - |
Purdue University
| 3 years |
Thomas P. McDuffee | M | - |
Purdue University
| 6 years |
William W. Reid | M | 75 |
Purdue University
| 6 years |
Julie Cherrington | M | 66 | 1 years | |
Ronald Parratt | M | 75 |
Purdue University
| 6 years |
Wayne Clinton Ramsey | M | - |
Purdue University
| 5 years |
Fredric D. Price | M | 78 | 4 years | |
Joseph C. Tucker | M | 76 |
Purdue University
| 4 years |
Christopher Starr | M | 71 | 9 years | |
Dan Spiegelman | M | 65 | 8 years | |
Kim Tsuchimoto | F | 61 | 8 years | |
Louis C. Drapeau | M | 79 | 3 years | |
Jill Howe | F | 48 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Elaine Heron
- Personal Network